Went public 02/09/01 at $11 per share
Filing Range: 7.5 million shares at $11 to $13
Shares Outstanding: 39.15 million shares
Underwriters: Lehman Brothers/CIBC World Markets Inc/Dain Rauscher
Wessels/Robert W. Baird & Co./Fidelity Capital Markets
Company Counsel: Wilson Sonsini Goodrich & Rosati
Manager Counsel: Mintz Levin Cohn Ferris Glovsky & Popeo
Auditor: Ernst & Young LLP
Develops enzymes and systems for manipulating DNA & RNA. The company’s product is used as a genetic analysis tool and aims to provide a new paradigm for genetic/DNA-based identification and the monitoring of diagnostic outcomes.
Schroder Ventures International Life Sciences
Venture Investors Management LLC
Invesco Private Capital
CIBC Capital Partners
Galleon Management Inc.
Scudder Kemper Investments Inc.
Essex Venture Partners
Burrill & Co.
Number of Round Amount
Round # Round Date Stage Investors( $ thousands)
1 10/16/1998 3 Expansion 9400.0
2 08/31/1999 7 Later Stage 19500.2
3 07/26/2000 17 Expansion 48000.0
(Data in $ million)
Total Revenues: $11.4
Net Income: (25.6)